Bicara Therapeutics Inc. reported second quarter 2026 financial results and announced significant executive leadership transitions effective January 1, 2027. Ryan Cohlhepp will succeed Claire Mazumdar as CEO, while Tanya Green will become COO; Jenn Larson replaces Ivan Hyep as CFO effective August 12, 2026. The company reported a net loss of $55.4 million and R&D expenses of $45.8 million for the quarter ended June 30, 2026. Cash and equivalents stood at $96.6 million with marketable securities of $400.7 million, providing a runway into early 2029. The company is advancing ficerafusp alfa in head and neck cancer, initiating the FORTIFI-FLEX study and targeting substantial enrollment for the pivotal FORTIFI-HN01 trial by year-end to enable interim analysis results in mid-2027. Bicara Therapeutics Inc. operates as a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors.

Bicara Therapeutics Inc. announced that founding board member Kiran Mazumdar-Shaw resigned from the Board and its Nominating and Corporate Governance Committee, effective July 28, 2026. The Board simultaneously appointed Jeremy Bender, Ph.D., and Christy Oliger as Class I and Class II directors, respectively, also effective July 28, 2026. Consequently, the Board size increased from nine to ten directors. Dr. Bender joins the Audit Committee, while Ms. Oliger joins the Nominating and Corporate Governance Committee. Both new directors were appointed to a newly formed Launch Readiness Committee, chaired by Kate Haviland, to provide strategic guidance on commercialization and launch readiness for the company's lead asset, ficerafusp alfa. The company is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors.